ICU MED INC's ticker is ICUI and the CUSIP is 44930G107. A total of 292 filers reported holding ICU MED INC in Q1 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $36,313,947 | -35.3% | 305,134 | -3.1% | 0.28% | -31.0% |
Q2 2023 | $56,139,897 | +13.7% | 315,056 | +5.3% | 0.40% | +6.7% |
Q1 2023 | $49,374,004 | +3.5% | 299,308 | -1.2% | 0.38% | +2.2% |
Q4 2022 | $47,691,243 | +0.5% | 302,840 | -3.8% | 0.37% | -5.9% |
Q3 2022 | $47,431,000 | -1.3% | 314,952 | +7.7% | 0.39% | +6.8% |
Q2 2022 | $48,065,000 | -27.6% | 292,379 | -1.9% | 0.36% | -15.3% |
Q1 2022 | $66,350,000 | -2.1% | 298,019 | +3.5% | 0.43% | +0.2% |
Q4 2021 | $67,801,000 | -11.3% | 287,872 | -12.1% | 0.43% | -16.5% |
Q3 2021 | $76,437,000 | +14.2% | 327,523 | +0.7% | 0.52% | +17.3% |
Q2 2021 | $66,917,000 | -2.5% | 325,153 | -2.7% | 0.44% | -5.2% |
Q1 2021 | $68,638,000 | -13.7% | 334,103 | -9.9% | 0.46% | -20.2% |
Q4 2020 | $79,492,000 | +22.7% | 370,610 | +4.6% | 0.58% | +4.3% |
Q3 2020 | $64,768,000 | -4.8% | 354,388 | -4.0% | 0.56% | -7.8% |
Q2 2020 | $68,015,000 | -5.5% | 369,017 | +3.5% | 0.60% | -21.9% |
Q1 2020 | $71,951,000 | +10.2% | 356,596 | +2.2% | 0.77% | +52.6% |
Q4 2019 | $65,269,000 | +28.7% | 348,812 | +9.8% | 0.51% | +21.1% |
Q3 2019 | $50,697,000 | -9.9% | 317,648 | +42.2% | 0.42% | -20.7% |
Q2 2019 | $56,277,000 | +5.0% | 223,402 | -0.3% | 0.53% | 0.0% |
Q1 2019 | $53,615,000 | +1.9% | 224,023 | -2.2% | 0.53% | -9.1% |
Q4 2018 | $52,615,000 | -1.0% | 229,130 | +21.9% | 0.58% | +20.3% |
Q3 2018 | $53,126,000 | -40.3% | 187,891 | -38.0% | 0.48% | -42.1% |
Q2 2018 | $88,958,000 | -2.1% | 302,942 | -15.9% | 0.83% | -6.0% |
Q1 2018 | $90,907,000 | +7.1% | 360,172 | -8.3% | 0.89% | +12.3% |
Q4 2017 | $84,855,000 | +6.5% | 392,848 | -8.4% | 0.79% | -0.6% |
Q3 2017 | $79,700,000 | -4.7% | 428,839 | -11.6% | 0.79% | -11.3% |
Q2 2017 | $83,622,000 | -12.8% | 484,942 | -22.8% | 0.90% | -12.8% |
Q1 2017 | $95,882,000 | +4.2% | 627,910 | +0.5% | 1.03% | -0.5% |
Q4 2016 | $92,059,000 | +19.2% | 624,762 | +2.1% | 1.03% | +11.2% |
Q3 2016 | $77,227,000 | +19.0% | 611,625 | +6.3% | 0.93% | +12.4% |
Q2 2016 | $64,894,000 | +21.5% | 575,561 | +12.2% | 0.82% | +12.1% |
Q1 2016 | $53,396,000 | +5.9% | 512,923 | +14.8% | 0.74% | +5.4% |
Q4 2015 | $50,406,000 | +5.8% | 446,945 | +2.7% | 0.70% | -3.7% |
Q3 2015 | $47,647,000 | +8.7% | 435,131 | -5.0% | 0.72% | +23.7% |
Q2 2015 | $43,835,000 | -2.0% | 458,249 | -4.6% | 0.59% | -7.7% |
Q1 2015 | $44,737,000 | +18.1% | 480,320 | +3.9% | 0.64% | +15.7% |
Q4 2014 | $37,867,000 | +8.1% | 462,353 | -15.3% | 0.55% | +1.5% |
Q3 2014 | $35,016,000 | +17.8% | 545,599 | +11.6% | 0.54% | +21.3% |
Q2 2014 | $29,720,000 | +19.2% | 488,740 | +17.4% | 0.45% | +12.3% |
Q1 2014 | $24,934,000 | +13.5% | 416,408 | +20.7% | 0.40% | +8.8% |
Q4 2013 | $21,976,000 | +32.6% | 344,929 | +41.4% | 0.36% | +14.8% |
Q3 2013 | $16,569,000 | -4.6% | 243,909 | +1.2% | 0.32% | -13.4% |
Q2 2013 | $17,371,000 | – | 241,072 | – | 0.37% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
NUANCE INVESTMENTS, LLC | 1,035,101 | $212,651,000 | 3.97% |
EVR Research LP | 22,000 | $4,520,000 | 3.44% |
Tamarack Advisers, LP | 70,000 | $14,381,000 | 2.95% |
Nitorum Capital, L.P. | 252,668 | $51,908,000 | 2.56% |
PFM Health Sciences, LP | 290,661 | $59,713,000 | 1.82% |
KIRR MARBACH & CO LLC /IN/ | 22,298 | $4,581,000 | 1.33% |
Findlay Park Partners LLP | 671,136 | $137,878,000 | 0.96% |
PURA VIDA INVESTMENTS, LLC | 148,548 | $30,518,000 | 0.87% |
Redmile Group, LLC | 224,154 | $46,050,000 | 0.65% |
Canvas Wealth Advisors, LLC | 5,177 | $1,064,000 | 0.62% |